TransCode Therapeutics
Boston, Massachusetts, United States · Biotechnology, Health Care, Medical
TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The company’s lead therapeutic candidate, TTX
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 7
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (RNAZ)
- Website
- www.transcodetherapeutics.com
- Company page
Recent activity at TransCode Therapeutics
- : SEC 8-K (8.01): On October 28, 2026, TransCode Therapeutics, Inc. announced through a press release that its board of directors has initiated a formal strategic process to evaluate opportunities aimed at maximizing the value of the Company and its oncology portfolio, which includes their lead product candidate, TTX-MC138. This strategic initiative reflects the Company’s commitment to enhancing shareholder value and responding to market opportunities. The move may involve various actions, though specific details regarding potential transactions or partnerships have not yet been disclosed.
- : SEC 8-K (1.01): On October 1, 2026, TransCode Therapeutics, Inc. entered into a material definitive agreement with YA II PN, Ltd. (Yorkville) concerning their Standby Equity Purchase Agreement (SEPA) dated April 6, 2026. The Company made a prepayment of $840,975 to Yorkville, which included the outstanding principal of $759,000 on convertible promissory notes, as well as a prepayment premium and accrued interest. This prepayment was made in connection with a waiver agreement whereby Yorkville agreed to waive any Amortization Events related to the company's share price performance through October 31, 2026. Following this transaction, the total outstanding principal on the notes is approximately $4.1 million, and specific conditions regarding payment obligations were established in the event of future amortization events.
- : SEC 8-K (8.01): On September 28, 2026, TransCode Therapeutics, Inc. announced updated clinical data from its Phase 1a dose clinical trial of TTX-MC138. This press release highlights the latest findings and developments in their clinical research, which may have strategic implications for the company's future therapies and market positioning. The updated data may impact investor perception and the company's operational strategies moving forward. The announcement is significant as it reflects ongoing progress in clinical trials for their therapeutic pipeline.
- : TransCode Therapeutics Announces CFO Departure
- : TransCode Therapeutics Appoints John Tattory as Interim Chief Financial Officer
- : SEC 8-K (5.02): On September 10, 2026, TransCode Therapeutics, Inc. announced that Thomas A. Fitzgerald, M.B.A. resigned from his roles as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, and a member of the Board of Directors. His resignation was effective as of September 9, 2026, the Separation Date. The filing indicates that Mr. Fitzgerald's departure was not due to any disagreement with the company, suggesting a smooth transition. This change is significant as it impacts the financial leadership and governance structure of the company during a critical phase.
- : SEC 8-K (8.01): On July 2, 2026, TransCode Therapeutics, Inc. commenced its 2026 Annual Meeting of Stockholders and adjourned it until July 20, 2026, due to pending review approval from Nasdaq for its initial listing application. While preliminary voting reports indicated support for all proposals, the adjournment was necessary to comply with Nasdaq Listing Rules which stipulate that the review must be completed before stockholder voting on certain proposals can occur. Stockholders are encouraged to vote by July 19, 2026, prior to the reconvened meeting, and the meeting is critical for the approval of the conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock, impacting the capital structure of the company.
- : SEC 8-K (7.01): On June 18, 2026, TransCode Therapeutics, Inc. posted a presentation to its website intended for use with investors, analysts, collaborators, and vendors. This presentation may be utilized by the company over time to enhance communications with stakeholders. The material is provided as Exhibit 99.1 to the filing, and it is not deemed filed under the Securities Exchange Act or incorporated by reference in other filings. The strategic implication of this disclosure is to maintain transparency and engage with key partners and investors as the company seeks to advance its business objectives.
- : SEC 8-K (8.01): On June 3, 2026, TransCode Therapeutics, Inc. announced further results of its Phase 1a dose escalation clinical trial with TTX-MC138 through a press release. The filing discusses the forward-looking statements regarding the timing, conduct, and expected results of their clinical trials, addressing potential risks involved in drug development, including financial stability and regulatory challenges. The event date is significant as it reflects recent advances in the company's therapeutic projects, which may impact investor confidence and market performance. The attached exhibit (99.1) contains the press release detailing these developments.
- : TransCode Therapeutics secures up to $20 million in flexible financing to support its Phase 2a trial for TTX-MC138, ensuring operational momentum into 2027/2028.
TransCode Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2026 | Funding Round | $20.0M |
| Dec 2024 | Venture | $8.0M |
| Apr 2023 | Venture | Undisclosed |
Leadership
- Tom Fitzgerald, Chief Financial Officer; Director
- Thomas A. Fitzgerald, M.B.A., Principal
- John Tattory, Chief Financial Officer
- Zdravka Medarova, Chief Technology Officer
Verified email and direct lines for TransCode Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
TransCode Therapeutics in the news
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer - Yahoo Finance (Oct 13, 2026)
- TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026 - BioSpace (Oct 26, 2026)
- TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio - PR Newswire (Oct 28, 2026)
- TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering - Business Wire (Jul 08, 2021)
- TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis - PR Newswire (Aug 31, 2026)
- TransCode Therapeutics, Inc. (RNAZ) Stock Price, News, Quote & History - Yahoo! Finance Canada (Apr 28, 2021)
- TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer - PR Newswire (May 27, 2026)
- TransCode Therapeutics, Inc. (RNAZ) stock price, news, quote and history - Yahoo Finance Singapore (Apr 28, 2021)
Companies similar to TransCode Therapeutics
- Santersus AG · Biotechnology, Health Care, Medical, Therapeutics
- Archeus Technologies · Biotechnology, Health Care, Medical, Therapeutics
- Monument Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
- Iylon · Biotechnology, Health Care, Medical, Therapeutics
- Solid IO · Biotechnology, Health Care, Medical, Therapeutics
About TransCode Therapeutics: questions and answers
What does TransCode Therapeutics do?
TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The company’s lead therapeutic candidate, TTX
Where is TransCode Therapeutics headquartered?
TransCode Therapeutics is headquartered in Boston, Massachusetts, United States.
How many employees does TransCode Therapeutics have?
TransCode Therapeutics has about 7 employees.
Has TransCode Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for TransCode Therapeutics. The most recent, Funding Round of $20.0M, was in Apr 2026.
What is the latest news on TransCode Therapeutics?
On Oct 28, 2026, SEC 8-K (8.01): On October 28, 2026, TransCode Therapeutics, Inc. announced through a press release that its board of directors has initiated a formal strategic process to evaluate opportunities aimed at maximizing the value of the Company and its oncology portfolio, which includes their lead produc
Is TransCode Therapeutics a public company?
Yes. TransCode Therapeutics is publicly traded under the ticker RNAZ.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy